• Contact
Saturday, July 26, 2025
Register
Login
European Press
Advertisement
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video
No Result
View All Result
European Press
No Result
View All Result

Restore Medical secures $23M for heart failure studies

8 July 2025
in Health
Reading Time: 2 mins read
A A
Restore Medical secures M for heart failure studies
ShareShareShareShareShare


Restore Medical, a medtech company focusing on heart failure therapies, announced the closing of a $23 million Series B funding round.
Pitango HealthTech co-led the round with the European Innovation Council (EIC) Fund, with participation from existing investors, including Peregrine Ventures.
WHAT IT DOES
Restore Medical treats heart failure with transcatheter therapies designed to restore hemodynamic balance and improve clinical outcomes. 
The company’s flagship product, ContraBand, is a reversible therapy for the treatment of left ventricular (LV) failure. The catheter-delivered implant is intended to leverage the right ventricle to provide support to the LV, improving LV ejection fraction and restoring ventricular geometry. 
The company will utilize the funds to finalize a European feasibility study for ContraBand and initiate a U.S.-based clinical study.
“We are proud to have the support of such a strong and diverse group of partners, including two global strategic investors, the European Innovation Council Fund and leading VCs such as Peregrine Ventures and Pitango HealthTech,” Gilad Marom, CEO of Restore Medical, said in a statement. 
“Their confidence in our vision, team and technology is a powerful endorsement. With encouraging clinical data and FDA Breakthrough Device designation, we are well positioned to advance this technology toward making a meaningful impact for patients worldwide.”
MARKET SNAPSHOT
Restore Medical received Breakthrough Device Designation from the FDA last year for its ContraBand device. 
This designation was specifically for the treatment of heart failure in patients with reduced ejection fraction who remain symptomatic despite maximally tolerated guideline-directed medical therapy and who have no significant pulmonary hypertension or right heart failure.
In 2023, Restore Medical completed enrollment in its clinical study with its ContraBand device. 
The feasibility, multi-center, prospective study enrolled 15 patients who were already on maximally tolerated guideline-directed medical therapy across five hospitals in Europe. 
In 2022, Restore Medical was awarded a $2.9 million (€2.5 million) grant and subject to a future milestone, an equity investment of $11.6 million (€10 million). 
The funds were used to help Restore Medical enhance its clinical development of ContraBand and further investigate the treatment’s safety and efficacy.
Other companies in the transcatheter space include Evident Vascular, which in March announced the successful closing of its Series B financing.
The funding was used to accelerate the development of the company’s advanced IVUS technology designed to enhance vascular imaging and patient outcomes and support 510(k) FDA clearance ahead of its U.S. market launch.
The California-based company developed AI-enabled transcatheter intravascular ultrasound technology that captures images inside a patient’s blood vessels to evaluate vascular disease and enhance image interpretation.  
Evident Vascular launched in 2023 after receiving a $35 million Series A financing round.
In 2023, Append Medical, developer of a non-invasive implant for transcatheter left atrial appendage exclusion, raised $4.35 million as part of an extended Series A round of funding.
The company develops the Appligator, a device designed to reduce stroke risk in AF patients by excluding the LAA to prevent blood clot leakage with a minimally invasive transseptal intervention, leaving no metal implant behind.
In 2021, Append Medical completed a $7.4 million (€6.2 million) Series A financing round. 

Credit: Source link

Related Posts:

  • Restore Medical secures M for heart failure studies
    Restore Medical secures $23M for heart failure studies
  • Atraverse Medical secures $29.4M in financing for expansion
    Atraverse Medical secures $29.4M in financing for expansion
  • Vantive will invest $1B for digitally-enabled kidney care, vital organ support
    Vantive will invest $1B for digitally-enabled kidney…
  • Surgify secures $7.9 million in Series A funding for global expansion
    Surgify secures $7.9 million in Series A funding for…
ShareTweetSendPinShare
Previous Post

KPMG, Hippocratic AI partner to address workforce shortage

Next Post

Mendaera gets FDA 510(k) clearance for handheld robotic system

Next Post
Mendaera gets FDA 510(k) clearance for handheld robotic system

Mendaera gets FDA 510(k) clearance for handheld robotic system

Recommended

Sophie Cunningham fires back at WNBA after getting fined

Sophie Cunningham fires back at WNBA after getting fined

24 July 2025
Emerging technologies in healthcare, part 8: Phantom Neuro

Emerging technologies in healthcare, part 8: Phantom Neuro

26 June 2025
Input VAT refund developments under CREATE MORE

Input VAT refund developments under CREATE MORE

9 July 2025
Trump administration backs out of plan to publish climate reports on NASA website

Trump administration backs out of plan to publish climate reports on NASA website

24 July 2025
Latest news bulletin | July 5th – Midday

Latest news bulletin | July 5th – Midday

14 July 2025
European Press

European-press.com shares the latest news from Europe and around the world. It covers topics such as business, technology, sports, health, entertainment, and lifestyle. Feel free to get in touch with us!

Disclaimer  Privacy Policy – EU  Imprint 

Contact Us

What’s New Here!

  • Panama did not cede sovereignty to the US, foreign minister tells Euronews
  • Brandon Nimmo propels Mets past Giants for fifth straight win
  • Pushing for the mainstream use of bamboo in construction
  • Latest news bulletin | July 15th – Midday

Subscribe to Our Newsletter

Copyright 2025 © EUROPEAN PRESS All rights on our posts reserved!

Translate »
European Press
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video

Copyright 2025 © EUROPEAN PRESS All rights on our posts reserved!

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
×